Shopping Cart 0
Cart Subtotal
AED 0

Alzheimers Disease - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 27525
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Alzheimer's Disease-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease-Pipeline Review, H2 2018, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 25, 56, 53, 3, 276, 102 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 41 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 11

Alzheimer's Disease-Overview 12

Alzheimer's Disease-Therapeutics Development 13

Alzheimer's Disease-Therapeutics Assessment 80

Alzheimer's Disease-Companies Involved in Therapeutics Development 107

Alzheimer's Disease-Drug Profiles 201

Alzheimer's Disease-Dormant Projects 1212

Alzheimer's Disease-Discontinued Products 1251

Alzheimer's Disease-Product Development Milestones 1258

Appendix 1270


List Of Figure

List of Figures

Number of Products under Development for Alzheimer's Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Alzheimer's Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Alzheimer's Disease-Pipeline by AB Science SA, H2 2018

Alzheimer's Disease-Pipeline by AbbVie Inc, H2 2018

Alzheimer's Disease-Pipeline by AC Immune SA, H2 2018

Alzheimer's Disease-Pipeline by Accera Inc, H2 2018

Alzheimer's Disease-Pipeline by Actinogen Medical Ltd, H2 2018

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, H2 2018

Alzheimer's Disease-Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Affichem SA, H2 2018

Alzheimer's Disease-Pipeline by AFFiRiS AG, H2 2018

Alzheimer's Disease-Pipeline by Alector LLC, H2 2018

Alzheimer's Disease-Pipeline by Allergan Plc, H2 2018

Alzheimer's Disease-Pipeline by Allgenesis Biotherapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Allinky Biopharma SL, H2 2018

Alzheimer's Disease-Pipeline by ALSP Inc, H2 2018

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, H2 2018

Alzheimer's Disease-Pipeline by Alzinova AB, H2 2018

Alzheimer's Disease-Pipeline by AlzProtect SAS, H2 2018

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Alzheimer's Disease-Pipeline by Amgen Inc, H2 2018

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp, H2 2018

Alzheimer's Disease-Pipeline by Annexon Inc, H2 2018

Alzheimer's Disease-Pipeline by Aphios Corp, H2 2018

Alzheimer's Disease-Pipeline by Apodemus AB, H2 2018

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences SL, H2 2018

Alzheimer's Disease-Pipeline by Araclon Biotech SL, H2 2018

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by ArmaGen Inc, H2 2018

Alzheimer's Disease-Pipeline by Asceneuron SA, H2 2018

Alzheimer's Disease-Pipeline by AstraZeneca Plc, H2 2018

Alzheimer's Disease-Pipeline by Aucta Pharmaceuticals LLC, H2 2018

Alzheimer's Disease-Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, H2 2018

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd, H2 2018

Alzheimer's Disease-Pipeline by Axsome Therapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Axxam SpA, H2 2018

Alzheimer's Disease-Pipeline by AZTherapies Inc, H2 2018

Alzheimer's Disease-Pipeline by Bactevo Ltd, H2 2018

Alzheimer's Disease-Pipeline by Beactica AB, H2 2018

Alzheimer's Disease-Pipeline by Berg LLC, H2 2018

Alzheimer's Disease-Pipeline by BioArctic AB, H2 2018

Alzheimer's Disease-Pipeline by Biogen Inc, H2 2018

Alzheimer's Disease-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018

Alzheimer's Disease-Pipeline by BioHealthonomics Inc, H2 2018

Alzheimer's Disease-Pipeline by BioXcel Therapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Alzheimer's Disease-Pipeline by Bolder Biotechnology Inc, H2 2018

Alzheimer's Disease-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Co, H2 2018

Alzheimer's Disease-Pipeline by Bsim2, H2 2018

Alzheimer's Disease-Pipeline by Cantabio Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Cardax Inc, H2 2018

Alzheimer's Disease-Pipeline by Carna Biosciences Inc, H2 2018

Alzheimer's Disease-Pipeline by Celon Pharma SA, H2 2018

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co Ltd, H2 2018

Alzheimer's Disease-Pipeline by Clera Inc, H2 2018

Alzheimer's Disease-Pipeline by Cognition Therapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Cognosci Inc, H2 2018

Alzheimer's Disease-Pipeline by CohBar Inc, H2 2018

Alzheimer's Disease-Pipeline by Corium International Inc, H2 2018

Alzheimer's Disease-Pipeline by Coronis NeuroSciences Ltd, H2 2018

Alzheimer's Disease-Pipeline by Cortice Biosciences Inc, H2 2018

Alzheimer's Disease-Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Alzheimer's Disease Therapeutic Products under Development, Key Players in Alzheimer's Disease Therapeutics, Alzheimer's Disease Pipeline Overview, Alzheimer's Disease Pipeline, Alzheimer's Disease Pipeline Assessment


Companies

AB Science SA

AbbVie Inc

AC Immune SA

Accera Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Affichem SA

AFFiRiS AG

Alector LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma SL

ALSP Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Amgen Inc

Anavex Life Sciences Corp

Annexon Inc

Aphios Corp

Apodemus AB

Applied Research using OMIC Sciences SL

Araclon Biotech SL

Archer Pharmaceuticals Inc

ArmaGen Inc

Asceneuron SA

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Auritec Pharmaceuticals Inc

Avanir Pharmaceuticals Inc

Avineuro Pharmaceuticals Inc

Axon Neuroscience SE

Axovant Sciences Ltd

Axsome Therapeutics Inc

Axxam SpA

AZTherapies Inc

Bactevo Ltd

Beactica AB

Berg LLC

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Bsim2

Cantabio Pharmaceuticals Inc

Cardax Inc

Carna Biosciences Inc

Celon Pharma SA

CHA Bio & Diostech Co Ltd

Clera Inc

Cognition Therapeutics Inc

Cognosci Inc

CohBar Inc

Corium International Inc

Coronis NeuroSciences Ltd

Cortice Biosciences Inc

Cotinga Pharmaceuticals Inc

Crossbeta Biosciences BV

CTD Holdings Inc

Cypralis Ltd

Daewoong Co Ltd

Daiichi Sankyo Co Ltd

DanPET AB

Daval International Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dongkook Pharmaceutical Co Ltd

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Epigen Biosciences Inc

F. Hoffmann-La Roche Ltd

GemVax & KAEL Co Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

GeneScience Pharmaceuticals Co Ltd

GlaxoSmithKline Plc

GliaCure Inc

Glialogix Inc

Golden Biotechnology Corp

Grifols SA

H. Lundbeck AS

Hemostemix Inc

Heptares Therapeutics Ltd

HitGen LTD

ICB International Inc

Ichor Medical Systems Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Immungenetics AG

Immunwork Inc

Impel NeuroPharma Inc

India Globalization Capital Inc

Inflazome Ltd

Instituto Biomar SA

Insys Therapeutics Inc

IntelGenx Corp

Intellect Neurosciences Inc

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

K-Stemcell Co Ltd

Kadmon Corp LLC

Karuna Pharmaceuticals Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Ltd

Lupin Ltd

M3 Biotechnology Inc

ManRos Therapeutics

MedDay SA

Medesis Pharma SA

MedImmune LLC

MEDRx Co Ltd

MEI Pharma Inc

MeiraGTx Holdings Plc

Merck & Co Inc

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

ModGene Pharma LLC

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeoNeuro SAS

Neuralstem Inc

Neuraltus Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Neuro Bio Ltd

Neuro-Sys SAS

Neurodyn Life Sciences Inc

NeuroGeneration Inc

NeuroGenetic Pharmaceuticals Inc

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

NeuroScientific Biopharmaceuticals Pty Ltd

Neurotez Inc

New World Laboratories Inc

NoNO Inc

Novartis AG

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

Oryzon Genomics SA

Otsuka Holdings Co Ltd

Ovensa Inc

Oxstem Ltd

P2D Inc

Pain Therapeutics Inc

Peptron Inc

Pharmasum Therapeutics AS

Pharnext SA

Phoenix Biotechnology Inc

Prevacus Inc

Priavoid GmbH

Probiodrug AG

Progenra Inc

ProMIS Neurosciences Inc

Proteome Sciences Plc

Prothena Corp Plc

QR Pharma Inc

Quimatryx SL

Radius Health Inc

Regenera Pharma Ltd

reMYND NV

Revalesio Corp

Rodin Therapeutics Inc

Rodos BioTarget GmbH

Sage Therapeutics Inc

Samjin Pharm Co Ltd

Samumed LLC

SanBio Inc

Sangamo Therapeutics Inc

Sanofi

SBI Pharmaceuticals Co Ltd

Sentinel Oncology Ltd

Serometrix LLC

Shionogi & Co Ltd

Shire Plc

Simcere Pharmaceutical Group

Spherium Biomed SL

Summit Therapeutics Plc

Suven Life Sciences Ltd

T3D Therapeutics Inc

Takeda Pharmaceutical Co Ltd

TechnoPhage SA

Teikoku Pharma USA Inc

Telocyte LLC

Tetra Discovery Partners LLC

Tonix Pharmaceuticals Holding Corp

Toyama Chemical Co Ltd

Treventis Corp

UCB SA

Varinel Inc

Virobay Inc

VLP Therapeutics LLC

Voyager Therapeutics Inc

vTv Therapeutics Inc

Vybion Inc

Xigen SA

Zensun (Shanghai) Sci & Tech Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Alzheimer's Disease-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease-Pipeline Review, H2 2018, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 25, 56, 53, 3, 276, 102 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 41 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 11

Alzheimer's Disease-Overview 12

Alzheimer's Disease-Therapeutics Development 13

Alzheimer's Disease-Therapeutics Assessment 80

Alzheimer's Disease-Companies Involved in Therapeutics Development 107

Alzheimer's Disease-Drug Profiles 201

Alzheimer's Disease-Dormant Projects 1212

Alzheimer's Disease-Discontinued Products 1251

Alzheimer's Disease-Product Development Milestones 1258

Appendix 1270


List Of Figure

List of Figures

Number of Products under Development for Alzheimer's Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Alzheimer's Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Alzheimer's Disease-Pipeline by AB Science SA, H2 2018

Alzheimer's Disease-Pipeline by AbbVie Inc, H2 2018

Alzheimer's Disease-Pipeline by AC Immune SA, H2 2018

Alzheimer's Disease-Pipeline by Accera Inc, H2 2018

Alzheimer's Disease-Pipeline by Actinogen Medical Ltd, H2 2018

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, H2 2018

Alzheimer's Disease-Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Affichem SA, H2 2018

Alzheimer's Disease-Pipeline by AFFiRiS AG, H2 2018

Alzheimer's Disease-Pipeline by Alector LLC, H2 2018

Alzheimer's Disease-Pipeline by Allergan Plc, H2 2018

Alzheimer's Disease-Pipeline by Allgenesis Biotherapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Allinky Biopharma SL, H2 2018

Alzheimer's Disease-Pipeline by ALSP Inc, H2 2018

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, H2 2018

Alzheimer's Disease-Pipeline by Alzinova AB, H2 2018

Alzheimer's Disease-Pipeline by AlzProtect SAS, H2 2018

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Alzheimer's Disease-Pipeline by Amgen Inc, H2 2018

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp, H2 2018

Alzheimer's Disease-Pipeline by Annexon Inc, H2 2018

Alzheimer's Disease-Pipeline by Aphios Corp, H2 2018

Alzheimer's Disease-Pipeline by Apodemus AB, H2 2018

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences SL, H2 2018

Alzheimer's Disease-Pipeline by Araclon Biotech SL, H2 2018

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by ArmaGen Inc, H2 2018

Alzheimer's Disease-Pipeline by Asceneuron SA, H2 2018

Alzheimer's Disease-Pipeline by AstraZeneca Plc, H2 2018

Alzheimer's Disease-Pipeline by Aucta Pharmaceuticals LLC, H2 2018

Alzheimer's Disease-Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, H2 2018

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd, H2 2018

Alzheimer's Disease-Pipeline by Axsome Therapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Axxam SpA, H2 2018

Alzheimer's Disease-Pipeline by AZTherapies Inc, H2 2018

Alzheimer's Disease-Pipeline by Bactevo Ltd, H2 2018

Alzheimer's Disease-Pipeline by Beactica AB, H2 2018

Alzheimer's Disease-Pipeline by Berg LLC, H2 2018

Alzheimer's Disease-Pipeline by BioArctic AB, H2 2018

Alzheimer's Disease-Pipeline by Biogen Inc, H2 2018

Alzheimer's Disease-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018

Alzheimer's Disease-Pipeline by BioHealthonomics Inc, H2 2018

Alzheimer's Disease-Pipeline by BioXcel Therapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Alzheimer's Disease-Pipeline by Bolder Biotechnology Inc, H2 2018

Alzheimer's Disease-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Co, H2 2018

Alzheimer's Disease-Pipeline by Bsim2, H2 2018

Alzheimer's Disease-Pipeline by Cantabio Pharmaceuticals Inc, H2 2018

Alzheimer's Disease-Pipeline by Cardax Inc, H2 2018

Alzheimer's Disease-Pipeline by Carna Biosciences Inc, H2 2018

Alzheimer's Disease-Pipeline by Celon Pharma SA, H2 2018

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co Ltd, H2 2018

Alzheimer's Disease-Pipeline by Clera Inc, H2 2018

Alzheimer's Disease-Pipeline by Cognition Therapeutics Inc, H2 2018

Alzheimer's Disease-Pipeline by Cognosci Inc, H2 2018

Alzheimer's Disease-Pipeline by CohBar Inc, H2 2018

Alzheimer's Disease-Pipeline by Corium International Inc, H2 2018

Alzheimer's Disease-Pipeline by Coronis NeuroSciences Ltd, H2 2018

Alzheimer's Disease-Pipeline by Cortice Biosciences Inc, H2 2018

Alzheimer's Disease-Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Alzheimer's Disease Therapeutic Products under Development, Key Players in Alzheimer's Disease Therapeutics, Alzheimer's Disease Pipeline Overview, Alzheimer's Disease Pipeline, Alzheimer's Disease Pipeline Assessment


Companies

AB Science SA

AbbVie Inc

AC Immune SA

Accera Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Affichem SA

AFFiRiS AG

Alector LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma SL

ALSP Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Amgen Inc

Anavex Life Sciences Corp

Annexon Inc

Aphios Corp

Apodemus AB

Applied Research using OMIC Sciences SL

Araclon Biotech SL

Archer Pharmaceuticals Inc

ArmaGen Inc

Asceneuron SA

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Auritec Pharmaceuticals Inc

Avanir Pharmaceuticals Inc

Avineuro Pharmaceuticals Inc

Axon Neuroscience SE

Axovant Sciences Ltd

Axsome Therapeutics Inc

Axxam SpA

AZTherapies Inc

Bactevo Ltd

Beactica AB

Berg LLC

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Bsim2

Cantabio Pharmaceuticals Inc

Cardax Inc

Carna Biosciences Inc

Celon Pharma SA

CHA Bio & Diostech Co Ltd

Clera Inc

Cognition Therapeutics Inc

Cognosci Inc

CohBar Inc

Corium International Inc

Coronis NeuroSciences Ltd

Cortice Biosciences Inc

Cotinga Pharmaceuticals Inc

Crossbeta Biosciences BV

CTD Holdings Inc

Cypralis Ltd

Daewoong Co Ltd

Daiichi Sankyo Co Ltd

DanPET AB

Daval International Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dongkook Pharmaceutical Co Ltd

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Epigen Biosciences Inc

F. Hoffmann-La Roche Ltd

GemVax & KAEL Co Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

GeneScience Pharmaceuticals Co Ltd

GlaxoSmithKline Plc

GliaCure Inc

Glialogix Inc

Golden Biotechnology Corp

Grifols SA

H. Lundbeck AS

Hemostemix Inc

Heptares Therapeutics Ltd

HitGen LTD

ICB International Inc

Ichor Medical Systems Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Immungenetics AG

Immunwork Inc

Impel NeuroPharma Inc

India Globalization Capital Inc

Inflazome Ltd

Instituto Biomar SA

Insys Therapeutics Inc

IntelGenx Corp

Intellect Neurosciences Inc

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

K-Stemcell Co Ltd

Kadmon Corp LLC

Karuna Pharmaceuticals Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Ltd

Lupin Ltd

M3 Biotechnology Inc

ManRos Therapeutics

MedDay SA

Medesis Pharma SA

MedImmune LLC

MEDRx Co Ltd

MEI Pharma Inc

MeiraGTx Holdings Plc

Merck & Co Inc

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

ModGene Pharma LLC

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeoNeuro SAS

Neuralstem Inc

Neuraltus Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Neuro Bio Ltd

Neuro-Sys SAS

Neurodyn Life Sciences Inc

NeuroGeneration Inc

NeuroGenetic Pharmaceuticals Inc

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

NeuroScientific Biopharmaceuticals Pty Ltd

Neurotez Inc

New World Laboratories Inc

NoNO Inc

Novartis AG

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

Oryzon Genomics SA

Otsuka Holdings Co Ltd

Ovensa Inc

Oxstem Ltd

P2D Inc

Pain Therapeutics Inc

Peptron Inc

Pharmasum Therapeutics AS

Pharnext SA

Phoenix Biotechnology Inc

Prevacus Inc

Priavoid GmbH

Probiodrug AG

Progenra Inc

ProMIS Neurosciences Inc

Proteome Sciences Plc

Prothena Corp Plc

QR Pharma Inc

Quimatryx SL

Radius Health Inc

Regenera Pharma Ltd

reMYND NV

Revalesio Corp

Rodin Therapeutics Inc

Rodos BioTarget GmbH

Sage Therapeutics Inc

Samjin Pharm Co Ltd

Samumed LLC

SanBio Inc

Sangamo Therapeutics Inc

Sanofi

SBI Pharmaceuticals Co Ltd

Sentinel Oncology Ltd

Serometrix LLC

Shionogi & Co Ltd

Shire Plc

Simcere Pharmaceutical Group

Spherium Biomed SL

Summit Therapeutics Plc

Suven Life Sciences Ltd

T3D Therapeutics Inc

Takeda Pharmaceutical Co Ltd

TechnoPhage SA

Teikoku Pharma USA Inc

Telocyte LLC

Tetra Discovery Partners LLC

Tonix Pharmaceuticals Holding Corp

Toyama Chemical Co Ltd

Treventis Corp

UCB SA

Varinel Inc

Virobay Inc

VLP Therapeutics LLC

Voyager Therapeutics Inc

vTv Therapeutics Inc

Vybion Inc

Xigen SA

Zensun (Shanghai) Sci & Tech Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd